open access

Vol 21, No 1 (2014)
Original articles
Submitted: 2013-04-15
Accepted: 2013-04-22
Published online: 2014-02-13
Get Citation

Evaluated plasma interleukin-18/interleukin-10 ratio is a risk factor for acute coronary syndromes in patients with stable angina pectoris

Qiaowen Li, Zhiliang Li, Xiaoyong Zhang, Yunjun Ruan, Jian Qiu
DOI: 10.5603/CJ.a2013.0057
·
Cardiol J 2014;21(1):83-88.

open access

Vol 21, No 1 (2014)
Original articles
Submitted: 2013-04-15
Accepted: 2013-04-22
Published online: 2014-02-13

Abstract

Background: Studies suggested that interleukin-18 (IL-18)/interleukin-10 (IL-10) ratio is an independent predictor of adverse cardiovascular events in patients with acute coronary syndromes (ACS). In this study we aimed to evaluate the predictive significance of IL-18/IL-10 for the occurrence of ACS in patients with stable angina pectoris (SAP) over a 40-month follow-up.

Methods: The IL-18, IL-10 levels of 257 patients with SAP were determined by Enzyme-Linked Immunosorbent Assay (ELISA). Two hundred and fifty-two patients, 42 of whom had ACS and 210 were event-free, were divided into two groups according to the presence or absence of the occurrence of ACS during the 40-month follow-up.

Results: Plasma IL-18 and IL-18/IL-10 ratios were both significantly higher (p = 0.001 and p = 0.044, respectively) among patients with ACS, however, IL-10 level was lower (p = 0.046) compared to the patients without ACS. The elevation of plasma IL-18/IL-10 ratio and the number of coronary artery lesions made the advantage ratio of ACS in patients with SAP increase 4.242 times and 1.942 times (p = 0.000 and p = 0.011, respectively).

Conclusions: Plasma IL-18 and IL-10 levels in patients with SAP are closely related to the occurrence of ACS, elevated IL-18/IL-10 ratio has a positive predictive value for the occurrence of ACS in patients with SAP.

Abstract

Background: Studies suggested that interleukin-18 (IL-18)/interleukin-10 (IL-10) ratio is an independent predictor of adverse cardiovascular events in patients with acute coronary syndromes (ACS). In this study we aimed to evaluate the predictive significance of IL-18/IL-10 for the occurrence of ACS in patients with stable angina pectoris (SAP) over a 40-month follow-up.

Methods: The IL-18, IL-10 levels of 257 patients with SAP were determined by Enzyme-Linked Immunosorbent Assay (ELISA). Two hundred and fifty-two patients, 42 of whom had ACS and 210 were event-free, were divided into two groups according to the presence or absence of the occurrence of ACS during the 40-month follow-up.

Results: Plasma IL-18 and IL-18/IL-10 ratios were both significantly higher (p = 0.001 and p = 0.044, respectively) among patients with ACS, however, IL-10 level was lower (p = 0.046) compared to the patients without ACS. The elevation of plasma IL-18/IL-10 ratio and the number of coronary artery lesions made the advantage ratio of ACS in patients with SAP increase 4.242 times and 1.942 times (p = 0.000 and p = 0.011, respectively).

Conclusions: Plasma IL-18 and IL-10 levels in patients with SAP are closely related to the occurrence of ACS, elevated IL-18/IL-10 ratio has a positive predictive value for the occurrence of ACS in patients with SAP.

Get Citation

Keywords

stable angina pectoris, acute coronary syndromes, interleukin 18, interleukin 10

About this article
Title

Evaluated plasma interleukin-18/interleukin-10 ratio is a risk factor for acute coronary syndromes in patients with stable angina pectoris

Journal

Cardiology Journal

Issue

Vol 21, No 1 (2014)

Pages

83-88

Published online

2014-02-13

Page views

1692

Article views/downloads

1397

DOI

10.5603/CJ.a2013.0057

Bibliographic record

Cardiol J 2014;21(1):83-88.

Keywords

stable angina pectoris
acute coronary syndromes
interleukin 18
interleukin 10

Authors

Qiaowen Li
Zhiliang Li
Xiaoyong Zhang
Yunjun Ruan
Jian Qiu

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl